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administration were examined by vaccine and type of setting including 
physician offices, pharmacies, and other medical settings (e.g., 
inpatient/outpatient hospitals, emergency rooms). RESULTS: Of those receiving 
ZOSTAVAX®, PNEUMOVAX® 23 and influenza vaccines, 25%, 1%, and 7%, 
respectively, received it at a pharmacy. Compared to other US regions, 
pharmacy-based vaccination for these 3 vaccines was generally higher in the 
western and southern regions. Overall, the mean (SD) paid amounts per enrollee 
per vaccine administration at the physician offices, pharmacies, and other 
medical settings were as follows: ZOSTAVAX® $208.7 (42.1), $168.5 (15.7), and 
$209.5 (50.8), respectively (p<0.05); PNEUMOVAX® 23 $65.6 (27.5), $55.0 (9.7), and 
$72.1 (50.0), respectively (p<0.05); and influenza $29.3 (15.3), $21.6 (6.6), and $24.2 
(13.1), respectively (p<0.05). The mean paid amounts also differed by geographic 
regions and type of health plan, with costs usually lower for the vaccinations 
given at the pharmacies. CONCLUSIONS: The average direct costs per adult 
vaccination were lower in pharmacies, compared to physician offices and other 
medical settings by 16-26% and 11-20 %, respectively. These results were mostly 
consistent across geographic regions and types of health plans. These data may 
help payer and policymaker understand economic value of adult vaccination in 
different settings, especially in pharmacies.  
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OBJECTIVES: Currently, diagnosis of a bloodstream infection relies on culture-
based methods and takes 2-3 days. The development of a rapid diagnostic tool 
has been deemed a high priority by the Infectious Disease Society of America. 
Available rapid tests are limited by the need to target specific pathogens. Rapid 
tests for universal detection of bacterial or fungal pathogens are in development. 
Commercialization of such a test will allow physicians to make rapid decisions, 
avoid unnecessary hospitalization, and decrease morbidity. No economic 
analyses have yet assessed the potential medical cost impacts of such a test. 
METHODS: We performed a decision tree analysis to estimate the potential 
medical cost consequences of a rapid test to detect bloodstream infection, using 
data from published literature and expert opinion. We considered potential 
impacts in the areas of diagnostic testing, prevention of diseases, and reduction 
in hospital admissions. Medicare pricing schedules were used, analyses were 
conducted from the health care payer perspective, and a base case cost of 
$20/test was used. RESULTS: Our model demonstrates that with population-wide 
implementation, the annual U.S. medical cost savings associated with decreased 
clinical diagnostic testing, reduced antimicrobial use, disease prevention, 
avoidance of hospitalization, and reduction in hospital length of stay could be 
$0.2, $0.3, $1.2, $1.1 and $1.6 billion, respectively. An increase in diagnostic 
testing cost to $40, $50 and $60/test lowers net savings by 3.6%, 5.4% and 7.2%, 
respectively. A tripling of the testing cost still allows for net savings of >$3.6 
billion to the health care system. CONCLUSIONS: Our analysis suggests that 
routine hospital-based use of a rapid diagnostic test for bacterial and fungal 
bloodstream infections would result in substantial savings to U.S. health care 
payers. If such a test were available, and its negative predictive value for 
bloodstream infection were very high, it would likely become a dominant 
diagnostic strategy.  
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OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C 
(HCV) in Germany (62% genotype 1). HCV is one of the leading causes for chronic 
liver disease. Experts have estimated that about 27% of end-stage cirrhosis and 
25% of hepatocellular carcinoma are associated with HCV. Although HCV is 
associated with high costs, reliable data are scarce in Germany. Aim of the study 
was to assess the costs for treating chronically infected HCV patients in routine 
care. METHODS: We conducted a retrospective multicenter observational study. 
Design was approved by an ethics committee and patients were asked for their 
informed consent. Health care utilization was extracted from doctor files in six 
medical centers. Costs were calculated using official fee-scales and statistics. 
Societal perspective was taken. RESULTS: In total, 315 patients were analyzed. 
The mean age was 49.4 years, 57.5% were male and 67.9% had a genotype-1 
infection. Most common routes of transmission were injection drug use (39.0%) 
and infection through blood products (15.9%). In 41.3% of patients route of 
transmission was unknown. The average total costs were €19,147 including 
ambulatory care (€1,686), pharmaceuticals (€14,875), inpatient care (€1,293) and 
sick leave (€1,293). Cost differences were observed between patients groups (mild 
HCV, moderate HCV and compensated cirrhosis, decompensated cirrhosis). 
Patients receiving a 16-week treatment had average total costs of €8,230. A 24-
week treatment resulted in €13,674, 48-week treatment in €25,396 and 72-week 
treatment in €41,175. In nearly 30% of patients treatment duration did not 
correspond to official recommendations. CONCLUSIONS: Treatment of HCV 
patients is associated with high costs mainly affected by length of antiviral 
therapy. It is inevitable to follow current guidelines and monitor patients closely 
in order to avoid unnecessary costs. The analysis is the basis for implementing 
new therapies which started with the introduction of protease inhibitors in 2011.  
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OBJECTIVES: To determine the economic and health care resource burden of 
seasonal Influenza, in the UK, using linked, individual patient, hospital and 
family doctor records, including mortality stratified by; age, risk factors and 
complications. METHODS: A cross-sectional observational study design was 
carried out using data derived from linked GPRD, between January 2001 and 
March 2009. Subjects included were; all those with family doctor coded episodes 
of care for acute respiratory events related to infection (influenza, upper and 
lower respiratory tract infections (LRTI), and Influenza like illness (ILI)). Analysis 
was stratified by age and ‘at risk’ conditions recommended for influenza 
vaccination in the UK. UK 2011 published reference costs were used. RESULTS: 
156,193 influenza episodes were recorded during the study period, with mean 
age 42.7 years (SD 20.3). Of these 1,592 (1.0%) were hospitalised with mean length 
of stay of 7 days; 1,182 (0.8%) deaths occurred within 28 days. The risk of 
hospitalisation and mortality was lower in those vaccinated; odds ratio 0.59 and 
0.78 respectively. Cardiovascular complications, COPD and LRTI were associated 
with the largest number of deaths. Highest mortality rates were in patients 
≥65yrs. Costs escalate with complicated influenza episodes (average cost 
influenza £2,264/hospitalisation vs. complicated influenza £9,384/hospitalisation) 
and age (≤64yrs £6,166/hospitalisation; ≥65yrs £11,674/hospitalisation). 
Respiratory and chronic heart disease risk status had highest overall costs, but 
CNS risk had highest cost per episode (£15,198/hospitalisation). CONCLUSIONS: 
This study, the first of its kind in the UK, demonstrates that seasonal influenza, 
even at a time of low overall activity, is associated with a substantial burden of 
illness, which is preventable by vaccination. This study is likely to underestimate 
the true impact of influenza due to; only capturing individuals who visit a 
physician, because most affected individuals self-diagnose, and the 
incompleteness and coding errors inherent within administrative databases.  
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OBJECTIVES: To evaluate health care utilization and costs of patients with 
aspergillosis within a large, commercially-insured population in the US. 
METHODS: Adults ≥18 years with at least one inpatient, emergency room, or 
outpatient medical claim with an aspergillosis diagnosis (ICD-9-CM 117.3 or 
484.6) between July 1, 2004 to March 1, 2011 and ≥6 months of pre-index and ≥1 
month of continuous post-index health plan and pharmacy benefit enrollment 
were identified from the MarketScan Research Databases. Patients with a diagnosis 
of aspergillosis in the pre-index period were excluded. Aspergillosis cases were 
propensity score-matched to a sample of controls without aspergillosis.. A 
general linear model was used to estimate total costs which were adjusted by 
the probability of remaining in the study to a given point in time (e.g., 90, 180, 
365 days). Incremental costs were calculated between cohorts and a bootstrap 
procedure was used to produce corresponding variation and 95% confidence 
interval estimates. RESULTS: Patients with aspergillosis (N= 5499; mean age: 57.8 
years; 48.6% female; 39.1% with cancer; 34% with an index diagnosis in the 
inpatient setting) were matched to 5499 controls (mean age: 58.3 years; 48.4% 
female; 40.3% with cancer). Aspergillosis cases had a higher proportion of 
hospitalizations and a longer average length of stay, as well as a higher rate of ER 
use and monthly outpatient office visits, laboratory tests, and outpatient 
prescriptions during follow-up than controls. All contrasts were significant at 
p<0.001. The estimated mean incremental costs of patients with aspergillosis, 
adjusted for the probability of remaining in the study for a given duration of 
follow-up time, were $22,732.99, $19,620.51 and $17,870.09 for durations of 90, 
180, and 365 days, respectively. CONCLUSIONS: The economic burden of 
aspergillosis is substantial. Patients with aspergillosis utilize significantly more 
health care and thus incur greater health care costs than do similar patients 
without aspergillosis.  
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OBJECTIVES: Low uptake of routinely recommended adult immunizations is a 
public health concern. Using data from peer-reviewed literature, we developed a 
customizable model to estimate the human and economic burden caused by four 
major adult vaccine-preventable diseases (VPD) in the United States and for each 
US state individually in 2010. METHODS: Three primary estimates were 
developed to populate the model: 1) estimated number of cases per year based 
on 2010 US Census population data and published incidence rates; 2) estimated 
direct medical costs of a single case; and 3) estimated indirect medical costs 
related to morbidity/lost productivity. Four major adult VPDs were examined: 1) 
influenza; 2) pneumococcal disease (both invasive disease and pneumonia); 3) 
herpes zoster; and 4) pertussis. RESULTS: Estimated US annual cost for the four 
adult VPDs was 15.1 billion (B) (10.4B for age ≥50). Among adults indicated for 
vaccination against the four VPDs, influenza (≥18yrs), pneumococcal disease 
